Results from KEYNOTE-B99: Phase 2 Study of First-Line (1L) Pembrolizumab (pembro) Plus Investigational Agents and Chemotherapy (chemo) for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
CANCER RESEARCH(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要